Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT Liability

Clin Pharmacol Ther. 2024 Jul;116(1):42-51. doi: 10.1002/cpt.3284. Epub 2024 May 2.

Abstract

Cardiac safety regulatory guidance for drug development has undergone several monumental shifts over the past decade as technological advancements, analysis models and study best practices have transformed this landscape. Once, clinical proarrhythmic risk assessment of a new chemical entity (NCE) was nearly exclusively evaluated in a dedicated thorough QT (TQT) study. However, since the introduction of the International Council for Harmonisation (ICH) E14/S7B Q&A 5.1 and 6.1 TQT substitutions, drug developers are offered an alternative pathway to evaluate proarrhythmic risk during an ascending dose study in healthy volunteers or during a powered patient study, respectively. In addition, the findings as well as the manner in which nonclinical studies are conducted (i.e., utilizing best practices) can dictate the need for a positive control in the clinical study and/or affect the labeling outcome. Drug sponsors are now faced with the option of pursuing a dedicated TQT study or requesting a TQT substitution. Potential factors influencing the choice of pathway include the NCE mechanism of action, pharmacokinetic properties, and safety profile, as well as business considerations. This tutorial will highlight the regulatory framework for integrated arrhythmia risk prediction models to outline drug safety, delineate potential reasons why a TQT substitution request may be rejected and discuss when a standalone TQT is recommended.

Publication types

  • Review

MeSH terms

  • Arrhythmias, Cardiac* / chemically induced
  • Clinical Trials as Topic / legislation & jurisprudence
  • Clinical Trials as Topic / methods
  • Drug Development / legislation & jurisprudence
  • Drug Development / methods
  • Drug-Related Side Effects and Adverse Reactions
  • Electrocardiography / drug effects
  • Humans
  • Long QT Syndrome* / chemically induced
  • Risk Assessment / methods